Skip to main content

ALT Competitors

profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

Altimmune Inc. News

Cramer's Mad Money Recap: PepsiCo, JPMorgan Chase, Goldman Sachs

Jim Cramer says investors need to watch out for next week's economic data, COVID news and bank earnings. He's got your game plan.

Medicinova Jumps on Phase 2 Progress With Alcohol-Abuse Drug

Medicinova's clinical trials found that its ibudilast reduced the odds of heavy drinking over time by 45% relative to a placebo.

Nanox Higher on Application to FDA for Medical Imaging System

Nanox shares climbed after the medical-imaging-tech company applied to the FDA for clearance of a system that produces scans of human body parts.

Altimmune Higher After Phase 1 Progress With Obesity Drug

Altimmune jumped after it reported progress from its Phase 1 trial of ALT-801, a drug for obesity and liver disease.

Altimmune's Covid Vaccine Candidate Placed on Clinical Hold

Altimmune says it doesn't expect 'a significant impact on the overall clinical development timeline.'

Breaking News

Morgan Stanley Stock Leads Gains As Banks Boost Dividends After Fed Stress Tests

Morgan Stanley, Wells Fargo, Bank of America and Goldman Sachs will lift their quarterly dividend, while JPMorgan will hold its steady following last week's Fed stress tests.

Nike Stock Slides As As Margin Pressures, China Worries Offset Q4 Earnings Beat

"We think we're well positioned for growth in fiscal year 2023 ... having said that, we did take a cautious approach to Greater China," said CFO Matthew Friend.

Stocks Higher, Bank Dividends, Nike, Playtika And Occidental- Five Things To Know

Stock futures higher on global growth bets; Morgan Stanley leads bank gains after dividend boost; Nike slides as margin pressures offset Q4 earnings beat; Playtika shares surge on report of Joffre Capital interest and Occidental shares jump as Buffett adds more to stake

Walgreens Stock Slides As Group Scraps Plan to Sell UK-based Boots

"As a result of market instability ... no third party has been able to make an offer that adequately reflects the high potential value of Boots," Walgreens said.